李宗㟨精品72集,黄图能看见奶头

Health Care Professionals

OUR MEDICINES

Santhera is passionate about medical science and about developing new medical treatments for patients with rare and other diseases. Our focus is on the development of therapies for rare neuromuscular and pulmonary conditions with high unmet medical needs.

Our pipeline

Santhera is building a Duchenne muscular dystrophy (DMD) product portfolio to treat patients irrespective of causative mutations, disease stage or age. A marketing authorization application for Puldysa® (idebenone) is currently under review by the European Medicines Agency. Santhera has an option to exclusively in-license vamorolone, a first-in-class anti-inflammatory drug candidate with novel mode of action, in all indications and all countries worldwide except Japan and South Korea. Vamorolone is currently investigated in a pivotal study in patients with DMD to replace standard corticosteroids. In February 2018, Santhera in-licensed from Polyphor a clinical stage selective inhibitor (lonodelestat, POL6014) of human neutrophil elastase with the potential to treat cystic fibrosis (CF) and other lung diseases. The pipeline also includes omigapil and an exploratory gene therapy approach targeting congenital muscular dystrophies.